Results 131 to 140 of about 212,640 (241)
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era
British Journal of Haematology, EarlyView.Summary
Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.Juan‐Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo, Manuel Pérez‐Encinas, José‐María Raya, María‐Teresa Gómez‐Casares, Francisca Ferrer‐Marín, Alberto Hernández‐Sánchez, María‐Laura Fox, Anna Angona, Beatriz Cuevas, María‐Isabel Mata‐Vázquez, Rosa Ayala, Natalia de las Heras, Elvira Mora, Valentín García‐Gutiérrez, Alicia Senín, Jasson Villarreal, Blanca Xicoy, Raúl Pérez‐López, María García‐Fortes, Sonia González de Villambrosia, Elena Magro, María‐José Ramírez, Paula Gómez, Angel Ramírez‐Payer, Clara Martínez‐Valverde, Lucía Pérez‐Lamas, Carmen García‐Hernández, Mercedes Gasior, Luis‐Miguel Juárez‐Salcedo, Francisco Ibáñez, María‐Luisa Antelo, Lucía Guerrero, Alberto Alvarez‐Larrán, Arturo Pereira, on behalf of the Spanish MPN Group (GEMFIN) +35 morewiley +1 more sourceTreatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukaemia patients: A multicentre real‐world study
British Journal of Haematology, EarlyView.Summary
Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two ...Desiree Kunadt, Sven Zukunft, Christoph Röllig, Stephan Metzelder, Andreas Burchert, Eva Wagner‐Drouet, Oliver Kriege, Christoph Schliemann, Matthias Stelljes, Julian Ronnacker, Wolfgang Bethge, Jan Frederic Weller, Björn Steffen, Gesine Bug, Khouloud Kouidri, Claudia Baldus, Lars Fransecky, Elisa Sala, Uwe Platzbecker, Klaus Metzeler, Sabine Kayser, Inken Hilgendorf, Andreas Hochhaus, Tim H. Brümmendorf, Edgar Jost, Anna Dorottya Doleschall, Thomas Schroeder, Jennifer Kaivers, Lambros Kordelas, Udo Holtick, Julia M. Unglaub, Tim Sauer, Paul Sebastian Jäger, Guido Kobbe, Elena Stauffer, Johanna Tischer, Tobias Herold, Normann Steiner, David Nachbaur, Nicolaus Kröger, Jochen J. Frietsch, Sabrina Kraus, Hermann Einsele, Mathias Hänel, Judith Schaffrath, William Krüger, Anne Brandenburg, Tobias A. W. Holderried, Laura Reinhardt, Markus Maulhardt, Christian Thiede, Martin Bornhäuser, Johannes Schetelig, Jan M. Middeke, Friedrich Stölzel, for the German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL) +55 morewiley +1 more sourceSalvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network (EMN) Italy
British Journal of Haematology, EarlyView.Summary
The extensive use of lenalidomide (Len) in the first‐line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len‐R) at first relapse. However, the outcome of Len‐R patients treated at first relapse after autologous haematopoietic stem cell transplantation (AHSCT) Gregorio Barilà, Angela Grassi, Valeria Ruocco, Carmine Liberatore, Edoardo Olivari, Martina Tinelli, Francesca Fazio, Sonia Morè, Emanuele Favero, Claudio Salvatore Cartia, Nicola Sgherza, Concetta Conticello, Roberto Mina, Martina Gherardini, Giuseppe Mele, Massimo Gentile, Anna Furlan, Massimiliano Arangio Febbo, Maria Livia Del Giudice, Ombretta Annibali, Bernardo Rossini, Edoardo Scomazzon, Marco Talarico, Enrica Antonia Martino, Claudio De Magistris, Francesca Fioritoni, Anna Maria Cafro, Laura Paris, Sara Pezzatti, Roberta Della Pepa, Paola Boggione, Giuseppe Pietrantuono, Valeria Tomarchio, Francesco Vassallo, Maria Luisa Pioltelli, Francesco Pisani, Antonia Cagnetta, Lorenzo De Paoli, Gabriele Buda, Elisabetta Antonioli, Monica Galli, Alberto Tosetto, Pellegrino Musto, Elena Zamagni, Francesca Patriarca, Silvia Mangiacavalli, Renato Zambello, Massimo Offidani, Maria Teresa Petrucci +48 morewiley +1 more sourceMinimal residual disease–guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype
British Journal of Haematology, EarlyView.Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin +15 morewiley +1 more sourceDistinct clinical and genetic characteristics of myelodysplastic syndrome in younger patients
British Journal of Haematology, EarlyView.Summary
Myelodysplastic neoplasms (formerly myelodysplastic syndromes, MDS) are heterogeneous clonal haematological malignancies that primarily affect the elderly, though a notable proportion of patients are diagnosed at younger ages. We retrospectively analysed 1437 patients diagnosed or treated at Asan Medical Center between 1989 and 2022, comparing ...Hyunkyung Park, Eun‐Ji Choi, Young‐Uk Cho, Yunsuk Choi, Han‐Seung Park, Jung‐Hee Lee, Joon Young Hur, Jisu Jeong, Seungah Cha, Yueun Lee, Young‐Shin Lee, Young‐Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Je‐Hwan Lee +15 morewiley +1 more sourceReal‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria
British Journal of Haematology, EarlyView.Summary
B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and ...Irene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, Thomas Melchardt, Michael Leisch, Eduard Schulz, Annkristin Heine, Peter Neumeister, Normann Steiner, Dominik Wolf, Wolfgang Willenbacher, Petra Pichler‐Izmir, Theresa Lentner, Johannes Clausen, Veronika Buxhofer‐Ausch, Sigrid Machherndl‐Spandl, Olga Saini, Dagmar Wipplinger, Holger Rumpold, Nina Worel, Werner Rabitsch, Axel Schulenburg, Hermine Agis, Maria‐Theresa Krauth +23 morewiley +1 more sourcePredicted microbiome‐associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia
British Journal of Haematology, EarlyView.Summary
Microbial metabolites are key regulators of host immunity, yet their functional impact in chronic lymphocytic leukaemia (CLL) remains unclear. Following up on our earlier observations of microbiome dysbiosis in CLL, we performed predictive metabolic profiling based on 16S ribosomal RNA (rRNA) sequencing of oral and stool samples collected from ...Monika Szelest, Joanna Zaleska, Michał Kiełbus, Magdalena Paziewska, Marta Masternak, Ewa Wawrzyniak, Aleksandra Kotkowska, Monika Siemieniuk‐Ryś, Marta Morawska, Elżbieta Kalicińska, Paula Jabłonowska‐Babij, Tomasz Wróbel, Anna Wolska‐Washer, Jerzy Zdzisław Błoński, Tadeusz Robak, Krzysztof Giannopoulos +15 morewiley +1 more sourceFunctional assessment of inherited myeloid neoplasm‐associated SAMD9L germline variants via Monoallelic CRISPR modelling
British Journal of Haematology, EarlyView.Summary
While the majority of myeloid neoplasms are sporadic, the increasing application of germline genetic testing has led the World Health Organization to designate ‘Myeloid malignancies with germline predisposition’ as a distinct clinical entity, carrying major implications for clinical care and research.Elena Vuelta, Alessandro Liquori, Matias Morín, Lucia Soletto, Miguel Ángel Marugal, Marta Santiago‐Balsera, Miguel Gallardo, Miguel Ángel Moreno‐Pelayo, José Cervera, Alejandra Sanjuan‐Pla +9 morewiley +1 more sourceReal-World Diagnostic Yield and Longitudinal Dynamics of Fluorescence In Situ Hybridization in Hematologic Malignancies: A Five-Year Retrospective Analysis of 1357 Patient Samples. [PDF]
Genes (Basel)Fumo R, Scala K, Gaeta S, D'Ardia A, Infante T, Ciancia G, Caputo A, Rosati A, Serio B, D'Antonio A, Zeppa P, Chetta M. +11 moreeuropepmc +1 more source